Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

Abstract

Docetaxel is an active single agent in previously treated patients with TCC of the urothelial tract. Therapy was well tolerated in this patient population but myelosuppression was frequent. Further study in previously untreated patients, both alone and in combination, is warranted.